We are live on
!
Find out more
GA
Greenspring Associates Portfolio holdings
AUM
$1.48B
1-Year Est. Return
61.93%
This Fund
S&P 500
This Quarter
Est. Return
+0.75%
1 Year Est. Return
+61.93%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.48B
AUM Growth
+$1.35B
(+1,076%)
Cap. Flow
+$1.39B
Cap. Flow
% of AUM
94.31%
Top 10 Holdings %
Top 10 Hldgs %
99.98%
Holding
17
New
9
Increased
1
Reduced
1
Closed
4
Top Buys
| 1 |
NEUE
NeueHealth
NEUE
|
+$747M |
| 2 |
WKME
WalkMe Ltd. Ordinary Shares
WKME
|
+$308M |
| 3 |
Xometry
XMTR
|
+$242M |
| 4 |
UiPath
PATH
|
+$135M |
| 5 |
Phathom Pharmaceuticals
PHAT
|
+$1.95M |
Top Sells
| 1 |
CrowdStrike
CRWD
|
+$2.73M |
| 2 |
10x Genomics
TXG
|
+$511K |
| 3 |
FINV
FinVolution Group
FINV
|
+$101K |
| 4 |
Pulmonx
LUNG
|
+$26K |
Sector Composition
| 1 | Healthcare | 53.71% |
| 2 | Technology | 29.07% |
| 3 | Industrials | 16.36% |
| 4 | Financials | 0.86% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NEUE
1
DELISTED
NeueHealth
NEUE
| $748M | 50.59% |
+544,949
| New | +$747M |
|
|
WKME
2
DELISTED
WalkMe Ltd. Ordinary Shares
WKME
| $303M | 20.51% |
+10,366,855
| New | +$308M |
|
|
3
Xometry
XMTR
$5.44B
| $242M | 16.36% |
+2,768,466
| New | +$242M |
|
|
4
UiPath
PATH
$6.3B
| $125M | 8.46% |
+1,842,177
| New | +$135M |
|
|
NGM
5
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $31M | 2.1% |
1,573,357
| – | – |
|
|
6
Phathom Pharmaceuticals
PHAT
$873M
| $14.1M | 0.95% |
415,277
+54,338
| +15% | +$1.95M |
|
|
TWAV
7
TaoWeave Inc
TWAV
$4.04M
| $12.6M | 0.85% |
6,154
| – | – |
|
|
SMAR
8
DELISTED
Smartsheet Inc.
SMAR
| $1.31M | 0.09% |
+18,129
| New | +$1.13M |
|
9
Arcutis Biotherapeutics
ARQT
$3.56B
| $961K | 0.07% |
+35,210
| New | +$992K |
|
|
ZEN
10
DELISTED
ZENDESK INC
ZEN
| $119K | 0.01% |
+824
| New | +$116K |
|
|
FINV
11
FinVolution Group
FINV
$1.12B
| $118K | 0.01% |
12,412
-13,325
| -52% | -$101K |
|
|
SFIX
12
Stitch Fix
SFIX
$506M
| $86K | 0.01% |
+1,433
| New | +$73.4K |
|
13
Progyny
PGNY
$2.5B
| $80K | 0.01% |
+1,359
| New | +$76.3K |
|
|
14
CrowdStrike
CRWD
$207B
| – | – |
-59,920
| Closed | -$2.73M |
|
|
15
Pulmonx
LUNG
$59.1M
| – | – |
-566
| Closed | -$26K |
|
|
16
10x Genomics
TXG
$5.55B
| – | – |
-2,821
| Closed | -$511K |
|
Similar funds
A
UR
NNP
JJIJ
BAWC
RP
NIA
SCM
Greenspring Associates's Q2 2021 Portfolio in Review
As of Q2 2021, Greenspring Associates held 17 positions worth $1.48B, up 1,076% from $126M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Greenspring Associates deployed $1.39B of net new capital in Q2 2021, opening 9 new positions and adding to 1 existing holding. Its largest new stake was NeueHealth: 544,949 shares worth $748M.
By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 48% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was FinVolution Group, an estimated $101K trimmed.
- Greenspring Associates's largest Q2 2021 buy was NeueHealth: 544,949 shares worth $748M.
- Greenspring Associates added most to Phathom Pharmaceuticals in Q2 2021, an estimated $1.95M increase.
- Greenspring Associates's biggest Q2 2021 reduction was FinVolution Group, cutting an estimated $101K.
- Greenspring Associates fully exited CrowdStrike in Q2 2021, selling an estimated $2.73M.
- Greenspring Associates's ten largest holdings make up 100% of its $1.48B portfolio in Q2 2021.
- Greenspring Associates opened 9 new positions and closed 4 in Q2 2021.
- Greenspring Associates's portfolio value rose 1,076% quarter-over-quarter to $1.48B.
Based on Greenspring Associates's 13F filing for Q2 2021, filed 13 Aug 2021.